Pharma BD Deal Intelligence
Vertex's largest acquisition to date—$10B all-cash for Crinetics adds an already-approved oral acromegaly drug (PALSONIFY) plus atumelnant, a Phase 3 asset for congenital adrenal hyperplasia, giving Vertex a combined ~$5B peak-sales rare-endocrine franchise. The deal is funded partly through $4.5B in bridge financing, though it closes Q3 2026 with no track record yet on commercial execution.
Diversifies Vertex beyond CF into oral endocrinology with a launched drug + Phase 3 asset
Full analysis, sources & comparables →Vertex's $10B foray into endocrine disease with acromegaly drug Palsonify and CAH candidate atumelnant.
Vertex to acquire Crinetics for $85.00/share in cash, ~$10.0B equity value; adds PALSONIFY and atumelnant.
Vertex's largest acquisition to date; ~$5B combined peak sales; expected close Q3 2026; $4.5B committed bridge financing.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Vertex Pharmaceuticals Incorporated agreed on July 6, 2026 to acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash — an all-cash transaction valued at approximately $10.0 billion in equity (~$8.8 billion net of estimated cash acquired), Vertex's largest acquisition to date. The deal adds PALSONIFY (paltusotine), the first once-daily oral nonpeptide somatostatin receptor type 2 (SST2) agonist, FDA-approved in September 2025 for acromegaly, and atumelnant, a once-daily oral ACTH (MC2R) receptor antagonist in pivotal Phase 3 (CALM-CAH) for classic congenital adrenal hyperplasia and Phase 1/2b for ACTH-dependent Cushing's syndrome. Vertex cites a combined ~$5 billion peak-sales opportunity, expects to close in Q3 2026, and is funding the deal with cash on hand plus $4.5 billion of committed bridge financing from Bank of America and Morgan Stanley.
30K US cases/yr
Classic congenital adrenal hyperplasia (CAH), most often from 21-hydroxylase deficiency, is a rare autosomal-recessive disorder in which impaired cortisol synthesis drives compensatory ACTH excess and adrenal androgen overproduction. It affects roughly 1 in 10,000-15,000 births (~20,000-30,000 US patients). Lifelong supraphysiologic glucocorticoid replacement is standard of care but carries significant metabolic and growth toxicity.
For ~70 years the only therapy was supraphysiologic glucocorticoid/mineralocorticoid replacement. In December 2024 Neurocrine's crinecerfont (CRENESSITY), an oral CRF1 receptor antagonist that lowers ACTH at the pituitary, became the first approved non-glucocorticoid option. Crinetics' atumelnant differentiates by acting one step downstream — a selective oral ACTH (MC2R) receptor antagonist blocking ACTH action directly at the adrenal — with Phase 2 data showing up to ~80% mean reductions in androstenedione.
25K US cases/yr
Acromegaly is a rare, chronic endocrine disorder driven by excess growth hormone, almost always from a benign pituitary adenoma, producing elevated IGF-1, acral and soft-tissue overgrowth, and serious cardiometabolic complications. US prevalence is estimated at roughly 25,000 patients with about 3,000 new cases per year in a claims-based analysis. First-line medical therapy is chronic injectable somatostatin analogs, leaving a clear opening for an oral option.
Standard of care is injectable somatostatin analogs — octreotide LAR (Sandostatin LAR) and lanreotide (Somatuline Depot), both somatostatin receptor agonists — plus pasireotide (Signifor LAR) and the GH-receptor antagonist pegvisomant (Somavert). The only prior oral option is octreotide capsules (Mycapssa). PALSONIFY (paltusotine) is positioned as the first once-daily oral nonpeptide SST2 agonist, trading monthly injections for daily oral dosing.
Vertex and Crinetics announced a definitive merger agreement for $85.00 per share in cash (~$10.0B equity, ~$8.8B net of cash), unanimously approved by both boards, expected to close in Q3 2026.
The deal moves Vertex into endocrinology, pairing marketed PALSONIFY with Phase 3 atumelnant for a stated ~$5B combined peak-sales opportunity; funded via cash plus $4.5B committed bridge financing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. (this deal) | 2026 | $10.0B | 68 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / ViaCyte Inc. | 2022 | $320M | 60 |
← Browse all deals · How we score deals
More: 2026 deals · Vertex Pharmaceuticals Incorporated deals · Metabolic deals